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Summary Nasal continuous positive airway pressure (CPAP) is generally recommended for the
treatment of obstructive sleep apnoea. CPAP lowers the cardiovascular morbidity and mortal-
ity associated with severe obstructive sleep apnoea. At least 50% of patients presenting with
chronic heart failure (HF) have sleep apnoea; a subset of these patients may have obstructive
sleep apnoea and may derive a survival beneﬁt from CPAP. However, this population is also
prone to developing central sleep apnoea, Cheyne-Stokes respiration or both (CSA/CSR), for
which CPAP lowers the apnoea-hypopnoea index only partially and for which the overall effect
of CPAP on survival remains to be determined, particularly as it has been observed to increase
the mortality rate in subsets of patients. Other treatments may prove effective in patients with
chronic HF and CSA/CSR, although none, thus far, has been found to confer a survival bene-
ﬁt. New ventilatory modes include bi-level positive airway pressure and automated adaptive
servoventilation, the latter being most effective against CSA/CSR. Measures that can alleviate
CSA/CSR indirectly include beta-adrenergic blockers and renin-angiotensin-aldosterone system
inhibitors, nocturnal supplemental oxygen and cardiac resynchronization therapy (CRT). The
effects of theophylline, acetazolamide and nocturnal CO have also been studied. The second2
part of this review describes the applications and effects of therapies that are available for
sleep apnoea in patients with chronic HF.
© 2009 Elsevier Masson SAS. All rights reserved.
MOTS CLÉS
Apnée du sommeil ;
Résumé La ventilation en pression positive continue (VPPC) par masque faciale est générale-
ment recommandée pour traiter l’apnée du sommeil obstructive (ASO). Ce mode de ventilation
réduit la morbidité et la mortalité cardiovasculaires associées aux ASO sévères. Chez les sujets
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Insufﬁsance
cardiaque
souffrant d’insufﬁsance cardiaque chronique, plus de la moitié ont une apnée du sommeil.
Ceux atteints d’ASO semblent avoir un pronostic vital amélioré par la VPPC. Cependant, les
patients insufﬁsants cardiaques ont souvent une apnée du sommeil d’origine centrale et/ou
une respiration de Cheyne-Stokes (ASC/RCS). Chez eux, la VPPC améliore l’ASC/RCS de fac¸on
inconstante et l’impact sur l’espérance de vie reste à préciser, d’autant plus que la VPPC a
pu être responsable d’une surmortalité chez certains de ces patients. D’autres traitements
s’avèrent efﬁcaces contre l’ASC/RCS chez l’insufﬁsant cardiaque, mais à ce jour, aucun n’a
montré qu’il apportait un bénéﬁce en termes de survie. Il s’agit d’appareils de ventilation pou-
vant délivrer deux niveaux de pression positive ou bien de servoventilateurs ayant des capacités
d’adaptation automatique des pressions inspiratoires et expiratoires particulièrement efﬁcaces
contre l’ASC/RCS. D’autres thérapeutiques peuvent améliorer indirectement l’ASC/RCS, comme
les -bloquants, les inhibiteurs du système rénine-angiotensine-aldostérone, l’oxygénothérapie
nocturne et la resynchronisation du myocarde par stimulation cardiaque. Les effets de la théo-
phylline, de l’acétazolamide et de l’enrichissement de l’air inspiré en dioxide de carbone
pendant le sommeil ont également été étudiés. La seconde partie de cette revue décrit les
applications et les effets des thérapeutiques disponibles contre l’apnée du sommeil chez les
patients atteints d’insufﬁsance cardiaque chronique.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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Obbreviations
HI apnoea-hypopnoea index
F heart failure
PAP continuous positive airway pressure
RT cardiac resynchronization therapy
SA central sleep apnoea
SR Cheyne-Stokes respiration
VEF left ventricular ejection fraction
SA obstructive sleep apnoea
aCO2 partial pressure of carbon dioxide in the arterial
blood
CO2 partial pressure of carbon dioxide
ntroduction
asal CPAP is generally recommended for the treatment of
SA, including for patients presenting with cardiovascular
isorders [1]. CPAP lowers the cardiovascular morbidity and
ortality associated with severe OSA [2]. At least half of the
atients who present with chronic HF have sleep apnoea;
subset of these patients may have OSA, i.e., greater or
qual 50% of abnormal respiratory events during sleep are of
bstructive pattern [3,4], and may derive a survival beneﬁt
rom CPAP [5—8]. However, this population is also prone to
eveloping CSA, CSR or both (CSA/CSR) [3,4], for which CPAP
owers the apnoea-hypopnoea index (AHI; deﬁned as the
umber of apnoeas and hypopnoeas per hour of sleep) only
artially. The overall effect of CPAP on survival remains to be
etermined, particularly as it has been observed to increase
he mortality rate in subsets of patients with chronic HF
nd CSA/CSR [9,10]. Other treatments may prove effective
n patients with chronic HF and CSA/CSR, although none,
hus far, has been found to confer a survival beneﬁt. New
entilatory modes include bi-level positive airway pressure
nd automated adaptive servoventilation. Measures that can
lleviate CSA/CSR indirectly include beta-adrenergic block-
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rrs and renin-angiotensin-aldosterone system inhibitors,
octurnal supplemental oxygen and CRT. The effects of
heophylline, acetazolamide and nocturnal CO2 have also
een studied. The second part of this review describes the
herapies currently available for sleep apnoea in patients
resenting with chronic HF. The impact of these treatments
n functional status, cardiac performance, morbidity and
ortality is still being evaluated.
herapies with direct effects on abnormal
leep-related respiratory events
lleviation of sleep apnoea by ventilation systems may
mprove cardiac performance.
ontinuous and bi-level positive airway
ressure
PAP is the treatment recommended for OSA in patients pre-
enting with chronic HF [5—8]. The continuous insufﬂation of
ir under pressure through a nasal or facial mask opposes the
accidity and collapsibility of the upper airways during inspi-
ation, maintaining the patency of the pharyngeal duct. In
hese patients, CPAP may improve cardiac function. In a ran-
omized study of 24 patients, 1month of CPAP increased the
ean LVEF from 25.0 to 33.8% [5]. These observations, how-
ver, were not conﬁrmed by Smith et al., who noted that OSA
as alleviated in the absence of changes in indices of car-
iac function or functional status [7]. CPAP has been found
o lower morbidity and mortality in patients with chronic
F and OSA, with no serious adverse cardiovascular effects
6,8]. However, although data are scarce, the treatment of
SA with CPAP appears to aggravate myocardial dysfunctionn patients presenting with chronic HF and atrial ﬁbrillation
1]. Measurements made during cardiac catheterization in
ne study showed a fall in cardiac index in six patients with
trial ﬁbrillation, compared with in ﬁve patients in sinus
hythm, when up to 10 cm H2O of CPAP was applied for
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30minutes [11]. However, this short-term study was per-
formed in only a few patients presenting with chronic HF,
in the absence of sleep apnoea and while they were awake.
With non-permanent atrial ﬁbrillation, the risk of myocar-
dial intolerance of CPAP seems lower. One study reported
fewer recurrences of atrial ﬁbrillation after cardioversion
in patients with OSA treated with CPAP, compared with in
patients with untreated OSA [12]. Patients with chronic HF
were not excluded and greater than 50% were in New York
Heart Association functional class II, III or IV, with a mean
LVEF of 52± 13%. After 12months of treatment with CPAP,
the only signiﬁcant difference found between patients with
and without recurrences of atrial ﬁbrillation was correctly
applied treatment in the latter group. While no adverse
effect of CPAP has been reported, lack of compliance with
treatment may be a challenging issue. Furthermore, in OSA,
the severity of nocturnal O2 desaturation seems to be an
independent risk factor for the development of atrial ﬁbril-
lation [13]. The restoration of proper O2 saturation might
therefore explain the lower rate of recurrence of atrial ﬁb-
rillation associated with CPAP treatment.
Although CPAP acts via anatomical changes at the pharyn-
geal level, it may also correct CSA/CSR [9,10]. In chronic HF
due to systolic or diastolic dysfunction, the left ventricular
end-diastolic pressure is usually elevated. The insufﬂation
of air by the CPAP device maintains a constantly positive
intrathoracic pressure, narrowing the pressure difference
between the left intraventricular and intrathoracic pres-
sures [14—16]. The resulting decrease in left ventricular
end-diastolic pressure facilitates the ﬁlling of the failing
left ventricle and increases its stroke volume. In addition,
by raising the intrathoracic pressure, CPAP decreases the
venous return to the right heart and alleviates pulmonary
interstitial and myocardial congestion. The decrease in left
ventricular preload may also contribute to an increase in
cardiac output. The improvement in cardiac performance in
turn restores the central respiratory drive, which alleviates
CSA/CSR [17]. Fewer apnoeas are associated with a decrease
in sympathetic activity, fewer surges in heart rate and blood
pressure, less peripheral vasoconstriction and a decrease
in left ventricular afterload [16]. In addition, the decrease
in apnoeic-hypopnoeic events produced by CPAP limits the
number of dips in blood O2 saturation, which may increase
the cardiac output by relieving myocardial ischaemia.
In clinical studies, CPAP alleviated the manifestations
of chronic HF, improved the cardiac loading conditions,
increased LVEF and mitigated the severity of CSA/CSR
[9,10,18], although these changes have not been observed
systematically [9,10,19]. In contrast to OSA, the effects of
CPAP on CSA/CSR in patients presenting with chronic HF
are less prominent, in the order of a 40 to 60% decrease
in apnoeic events [10,20,21].
Sin et al. reported a higher survival rate among patients
with chronic HF and CSA/CSR treated with CPAP than among
untreated patients [18]. However, in a similar patient popu-
lation, the randomized CANPAP study found an early increase
in mortality in the group of patients assigned to CPAP
compared with untreated controls, perhaps because of a
decreased cardiac output due to the effects of CPAP on
left ventricular preload and ﬁlling; at 2 years, however,
the death and transplantation rates were similar in both
study groups [10]. In both the control and the CPAP-treated
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roups, mortality was due predominantly to progressive
hronic HF and sudden death. A more detailed post-hoc anal-
sis of the CANPAP study found that patients in whom the AHI
ad decreased below 15 after 3months of CPAP had a greater
ncrease in LVEF and a higher cardiac transplantation-free
urvival rate than the control group [9]. In that subgroup,
VEF increased by an average of 3.6% within 3months,
rom a mean baseline value of 25.6% — an increase signif-
cantly greater (p < 0.001) than that observed in the group
ot treated with CPAP. In contrast, no signiﬁcant difference
as observed in LVEF and heart transplant-free survival,
etween the group of patients whose AHI had remained
reater or equal to 15 after 3months of CPAP and the control
roup. Therefore, when CPAP is prescribed for the manage-
ent of CSA/CSR in patients with chronic HF, its effects on
HI need to be closely monitored during the ﬁrst 3months
f treatment, and it should be discontinued if its effects are
napparent or weak.
Between 1998 and 2004, the death and cardiac trans-
lantation rate in the combined CPAP and control groups
f the CANPAP trial fell from 20 per 100 person-years to
our per 100 person-years (p = 0.003) [10]. This profound
ecrease in the rate of the primary study endpoint, observed
n both groups, was independent of CPAP, and attributable
o changes in medications prescribed during the study. In
articular, the proportion of patients treated with beta-
drenergic blockers and spironolactone increased from 58
o 86% (p < 0.001) and from 14 to 41% (p = 0.001), respec-
ively, while the prescription of digoxin decreased from 72
o 36% (p = 0.002). The role played by pharmaceuticals in
SA/CSR will be further discussed later.
Because the air is simply insufﬂated continuously, CPAP
hould a priori be ineffective in the absence of sponta-
eous respiratory efforts, as in CSA/CSR, although this
ay not be the case, as discussed earlier. Bi-level venti-
ation systems have been tested in CSA/CSR, as they can
entilate a patient in the absence of breathing efforts,
orresponding to non-invasive assisted ventilation with a
asal or facial mask as well as CPAP [22,23]. In addition,
f the pressure applied by CPAP during expiration is iden-
ical to that applied during inspiration, bi-level ventilation
llows the setting of a low positive expiratory pressure for
atients who are uncomfortable when exhaling against a
igh positive pressure. The spontaneous/timed mode is usu-
lly selected [22,23]. Bi-level ventilation in the spontaneous
ode can be effective in OSA and is best implemented
ith a backup rate (timed mode) for CSA/CSR. For exam-
le, during spontaneous breathing, the patient is ventilated
n an assisted mode at a ﬁxed inspired pressure, which
s two to three times lower and ﬁxed during expiration.
hould CSA/CSR occur, the ventilator switches, in a few
econds, to controlled delivery of the same pressures as dur-
ng assisted ventilation and with a breathing rate preset at
2 to 15 breaths/minute. Upon the return of spontaneous
reathing, assisted ventilation resumes. Bi-level ventilation
as been found to be as effective as CPAP in alleviating
SA/CSR in patients with chronic HF [21—24]. In a study
f 16 patients, a 14-day delivery of CPAP, set at 8.5mbar,
as compared with the delivery of bi-level ventilation,
et at 8.5/3mbar, each for 14 days [23]. AHI was similarly
nd signiﬁcantly lowered, from 26.7± 10.7 at baseline to
.7± 5.6 and 6.5± 6.6 by CPAP and bi-level ventilation,
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espectively. Another study reported an increase in LVEF
rom 36.3± 2.9% to 46.0± 4.0% (p = 0.02) in seven patients
ith chronic HF and CSA/CSR treated with 3months of bi-
evel ventilation, compared with a non-signiﬁcant decrease
rom 34.1± 3.7% to 32.7± 3.2% in seven control patients
ho remained treated with medications only [22]. In that
tudy, the ﬁnal mean positive inspiratory/expiratory settings
f bi-level ventilation were 13.6± 3.6/7.9± 3.0 cm H2O and
he respiratory rate was 15.7± 0.5 breaths/minute. As in the
ase of CPAP, the decrease in central apnoea burden by bi-
evel ventilation in this population of patients with chronic
F was attributed mostly to the therapeutic effects of the
ncreased intrathoracic pressures on the failingmyocardium.
The highest compliance with and efﬁcacy of the system is
chieved by titrating the pressures of CPAP or bi-level ven-
ilation, which can be performed manually, adjusting the
ir pressures to lower the number of apnoeas-hypopnoeas
o a maximum tolerated by the patient [21]. These adjust-
ents in ventilation settings can be made at the bedside
y a sleep technician, in a single session or over several
octurnal sessions, during pulse-ﬁnger oxymetric or poly-
raphic/polysomnographic monitoring. In the absence of
sleep technician, these preliminary recordings can be
eviewed the following day, and the pressure re-adjusted for
he next night. In case of OSA, the device can be titrated
utomatically by algorithms based on an automated analy-
is of the upper airway resistance to airﬂow. Autotitrating
s theoretically contraindicated in patients with chronic HF,
ho might not tolerate the pressure levels applied auto-
atically, particularly when at home and unattended [1].
n practice, however, no adverse event was observed in a
ecent study of patients with chronic HF and OSA, in whom
PAP was autotitrated [7].
utomated adaptive servoventilation
octurnal automated adaptive servoventilation with a facial
ask is available for the treatment of CSA/CSR, and mixed
nd complex sleep apnoea. Its advantages are being stud-
ed, in particular in patients with chronic HF [19—21,24—26].
ith a 91% decrease in central apnoeas in a single night,
ervoventilators have been found to be more effective than
PAP, bi-level ventilation and nocturnal O2 supplementation,
or the management of CSA/CSR in patients with chronic
F [21]. Other small studies in patients with chronic HF
ave found unequivocally positive effects of servoventila-
ors on CSA/CSR [20,24,25], mixed sleep apnoea [20] and
omplex sleep apnoea [20,24] in acute settings. The efﬁ-
acy of servoventilators in the management of CSA/CSR has
een conﬁrmed at 1month [26] and 6months [19].
The physical characteristics of servoventilators are sim-
lar to those of CPAP or bi-level ventilation apparatuses.
owever, they include their own speciﬁc algorithms of
ssisted-controlled inspiration and controlled positive expi-
atory pressure. The algorithms are based on continuous,
ycle-by-cycle measurements of ventilation amplitude and
irﬂow pressure. A volume of air is delivered automatically
hrough the facial mask, at a pressure that compensates
or the incomplete tidal volume amplitude. The system
moothes the CSR cycles, during which the ventilatory
mplitude increases and decreases in phases separated by
pnoea or hypopnoea. Therapeutic ventilation can begin
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ith the default settings of the device manufacturer; for
xample, an end-expiratory pressure set at 5 cm H2O, sufﬁ-
ient to control any obstructive apnoea, and an inspiratory
ressure support between 3 and 10 cm H2O. The support
etting is the difference between end-inspiratory and end-
xpiratory pressures, with a minimum setting of 3 cm H2O
nd a maximum setting of 10 cm H2O. The default backup
espiratory rate is 15 breaths/minute, above or below which
he device tracks the patient’s spontaneous rate automat-
cally [21,26]. Populations of patients with chronic HF and
SA/CSR in whom servoventilators have been tested, pre-
ented with a large majority of central respiratory events, as
pposed to obstructive or mixed respiratory events [21,26].
Compared with the improvement in quality of life pro-
ided by CPAP in patients with common OSA, the effects
f CPAP [10] or servoventilation [19,24,26] in patients pre-
enting with chronic HF and CSA/CSR are more modest.
his is probably due to the mild or absent sleep apnoea-
nduced symptoms reported by these patients [19]. Trials
re in progress to examine the effects of servoventilation on
he morbidity and mortality of patients with chronic HF and
SA/CSR. The impact of servoventilation on cardiac func-
ion has been examined in a single randomized study of
5 patients [19]. After 6months of treatment, a 6% increase
n LVEF was observed in seven patients assigned to servoven-
ilation, as opposed to an approximately 3% decrease in six
atients assigned to CPAP — a statistically signiﬁcant differ-
nce. It is noteworthy that, in that randomized study, and
n contrast to other studies in similar patient populations
9,10], CPAP was not associated with an increase in LVEF at
months [19].
The long-term compliance with this cumbersome and
onstraining therapy remains to be determined. The sensa-
ion of suffocation associated with a facial mask is a major
ssue in patients with chronic HF, whose original chief com-
laint is discomfort due to dyspnoea. In studies of CPAP for
SA, patient compliance was limited mainly by the mask and
y local discomfort and complications.
herapies with indirect effects on
bnormal sleep-related respiratory events
hen these therapies improve cardiac performance, they
ay alleviate sleep apnoea.
edications for chronic congestive heart
ailure
he prominent effects of beta-adrenergic blockers and
pironolactone on the survival rate of patients enrolled
n the CANPAP trial [10] were reminiscent of earlier
bservations in patients with chronic HF treated with
eta-adrenergic blockers, angiotensin-converting enzyme
nhibitors and spironolactone, in whom the positive effects
n morbidity and mortality became apparent after 3 to
months of treatment. A positive effect of angiotensin-
onverting enzyme inhibitors on sleep apnoea has been
eported [27], as well as the alleviation of CSA/CSR by beta-
drenergic blockers in patients with chronic HF [28]. A mean
HI of 14± 11 was measured in 27 patients treated with
arvedilol 5 to 10mg/day, vs 33± 17 (p < 0.0001) in 18 similar
n
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patients who did not receive a beta-adrenergic blocker. In
another study, a decrease in mean AHI from 34± 13 before,
to 14± 13 after 6months of treatment with carvedilol
10mg twice daily (p = 0.003), was measured in 16 patients
[29]. In both studies, the decrease in AHI conferred by
carvedilol was due to an alleviation of central apnoea.
The alleviation of CSA/CSR conferred by these drugs might
be viewed as a marker of their beneﬁcial effects on the
myocardium.
Nocturnal oxygen supplementation
A 45% decrease in the number of central apnoeic events
has been reported in response to the acute delivery of
O2 (2 L/min) in patients with chronic HF who have sleep
apnoea, with no effect on obstructive events [21]. As men-
tioned earlier, in that overnight study, the decreases in
central apnoeas associated with CPAP, bi-level ventilation
and servoventilation were 48, 76 and 91%, respectively.
Another study in patients with chronic HF reported a 66%
decrease in central AHI by CPAP, and a 70% decrease by O2
delivered at 2 L/min, each for 3months [30]. In that study,
increases in LVEF and exercise capacity were treatment ben-
eﬁts conferred by CPAP, which were not observed in patients
treated with O2. After 3months of nocturnal O2 delivered
at a rate of 3 L/min, AHI decreased from 21.0± 10.8 to
10.0± 11.6 (p < 0.001) [31] — a 50% decrease in CSA/CSR
burden consistent with previous observations, which was
conﬁrmed recently [32]. Furthermore, in these same stud-
ies, LVEF increased after 3months of O2 supplementation
from 34.7± 10.4% to 38.2± 13.6% (p = 0.002) [31] and from
27± 9% to 37± 10% (p < 0.01), respectively [32], and this
was associated with a modest improvement in quality of
life. This delayed effect of nocturnal O2 is attributed to a
higher cardiac performance, associated with fewer abnor-
mal respiratory events of central origin. The delivery of
sufﬁcient supplemental O2 [31] prevents or limits the dips
in O2 during apnoea, hypopnoea (Fig. 1) and secondary
myocardial hypoxia. It also prevents the increase in myocar-
dial O2 demand due to the bursts of central sympathetic
activity occurring at the end of obstructive or central res-
piratory events [14,15,33]. Supplemental nocturnal O2 may
also:
• limit myocardial reperfusion injury due to the oxidative
stress caused by periodic hypoxia-normoxia occurring dur-
ing sleep apnoea [34];
• increase partial pressure of carbon dioxide in the arterial
blood (PaCO2), which decreases the severity of CSA/CSR,
because hypocapnoea is a key factor in its development
[17,35];
• mitigate hyperventilation and shorten the circulation
time in patients with chronic HF, limiting the severity of
hypocapnoea;
• modulate the sensitivity of the chemoreceptors in the res-
piratory control system, interfering with the CO2 and O2
ventilatory drive;
• promote the formation of oxyhaemoglobin instead of car-
boxyhaemoglobin, which increases PaCO2;
• counteract hypoxia, which participates in the prolonga-
tion of apnoea when vagal afferent activity is stimulated
by pulmonary congestion, resulting in inhibitory respira-
tory reﬂex.
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The ultimate health and survival beneﬁts conferred by
octurnal O2 supplementation in patients with chronic HF
nd sleep apnoea remain to be established.
ardiac pacing
he results of an initial study suggesting that cardiac pac-
ng might alleviate sleep apnoea [36] were not conﬁrmed
y a subsequent study, in which atrial overdrive pacing was
elivered by dual chamber pacemakers implanted for the
anagement of bradyarrhythmias, in patients presenting
ith OSA and without chronic HF [37]. During overdrive
trial pacing, the backup dual chamber pacing rate was
rogrammed between seven and 20 bpm above the mean
pontaneous nocturnal heart rate, for 24 hours and for
month. Furthermore, in a crossover study, 15 patients with
SA in absence of chronic HF who had no indication for
ardiac pacing, derived no beneﬁt from 1night of over-
rive atrial pacing [38]. In contrast, a decrease in AHI from
9.3± 12.1 to 12.3± 4.0 (p < 0.004) was measured after
week of overdrive atrial pacing in 7/19 (37%) patients
resenting with OSA and no chronic HF [39]. These con-
icting observations were not explained. Another study of
5 patients presenting with chronic HF and mixed sleep
pnoea found a decrease in AHI from 41± 20 to 27± 15
p < 0.005) in seven patients (47%) during nocturnal over-
rive atrial pacing with a dual chamber system [40]. The
atients in whom AHI had decreased had a greater propor-
ion of central events than the patients in whom overdrive
as ineffective. Importantly, that study, as well as another
tudy that found no effect on OSA and mixed sleep apnoea
onferred by up to 7months of dynamic atrial overdrive pac-
ng in patients with chronic HF [41], had recruited patients
ith clinical manifestations of OSA.
By contrast, all studies of the effects of CRT on CSA/CSR
n patients with chronic HF have shown a signiﬁcant decrease
n AHI, 3 to 6months after implantation of the system
42—47]. With respect to the effects of CRT on obstruc-
ive respiratory events, the results have been mixed, with
ither no change [42—44,46,47] or a decrease in AHI [48].
hen CRT has alleviating effects on OSA in patients with
hronic HF, it might be because the obstructive events are
ue to haemodynamic fragility instead of pure obstruction
f the upper airways. After 3 to 6months of CRT applied in
atients presenting with sleep apnoea, the increase in LVEF
anged between 4 and 14% [42—48]. The improvement in
ardiac function appeared to enhance the respiratory drive,
n effect that may decrease the rate of abnormal central
espiratory events, which, in turn, increases left ventric-
lar contractility. A correlation has been noted between
ecrease in CSA/CSR and pulmonary arterial systolic pres-
ure, and increase in LVEF after 3months of CRT [47]. A
ecrease in AHI associated with CRT has also been observed
n an acute setting [49].
Most studies of CRT and sleep apnoea have been per-
ormed without atrial overdrive pacing [42,44—47,49]. When
trial overdrive pacing was applied overnight after 6months
f CRT, in patients with OSA, it conferred no additional
herapeutic beneﬁts to those obtained with CRT [48].
ecently, a modest, though signiﬁcant, additional decrease
n AHI of central origin (23.8± 16.9 vs 21.5± 16.9; p < 0.01)
as observed when nocturnal atrial overdrive pacing at
716 P. Bordier
Figure 1. Nocturnal O2 supplementation in chronic heart failure and sleep apnoea. Patient with an apnoea-hypopnoea index (AHI: number
of apnoeas and hypopnoeas per hour of sleep) = 39.2, O2 desaturation index (ODI: number of dips in O2 per hour of sleep) = 35.4 and mean
nocturnal blood oxygen saturation (SaO2) = 90.7% on baseline nocturnal ventilation polygraphy. 1A and 1B. Baseline recordings, showing mixed
and obstructive apnoeas, respectively, with profound dips in O2. 1C and 1D. Recordings during 3 L/min of nocturnal O2 supplementation;
AHI = 4.5, ODI = 0.3 and mean nocturnal SaO2 = 97.9%. 1C. Mixed residual apnoeas with very mild O2 desaturation. The heart rate is stable
in this pacemaker recipient, with pacing at a backup rate of 70 bpm. Pacemaker programming was similar during baseline polygraphy.
T
P
shis indicates that the elimination of O2 desaturation during apnoeic e
rolonged, residual, abnormal respiratory event with obstructive hypop
hallow. ECG: electrocardiogram.vents may suppress the autonomic nervous system instability. 1D.
noea progressing toward apnoea; note that the dips in O2 remain
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CFigure 1. (Continued ).
15 bpm was added after 3months of successful CRT [43]. In
that study, a decrease in central AHI was measured, from
33.6± 14.3 before, to 23.8± 16.9 during CRT (p < 0.01),
before the addition of atrial overdrive pacing. It is note-
worthy that neither the new onset nor the worsening of
sleep apnoea has been reported during CRT [42—49]. While
c
o
t
a
[SA/CSR in patients with chronic HF is not, in itself, an indi-
ation for CRT, cardiac desynchronization in the presence
f CSA/CSR is a strong indication for implanting a CRT sys-
em, and the alleviation of sleep apnoea by CRT may be
valid criterion in the evaluation of the response to CRT
50].
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ther therapeutic trials
n a randomized, crossover study of 15 patients presenting
ith chronic HF and CSA/CSR, theophylline, administered
n an average dose of 3.3mg/kg for 5 days (mean plasma
oncentration = 11± 2mg/mL) decreased mean AHI from
7± 23 during placebo treatment, to 18± 17 during active
reatment (p = 0.001) [51]. This therapeutic effect was
ttributed to a theophylline-induced acceleration of the
eart rate, a valid hypothesis as tachycardia is one of the
ain compensatory mechanisms activated by cardiac insuf-
ciency. Theophylline also activates the central respiratory
rive. Its systematic prescription is limited by a high inci-
ence of adverse events, and, while its long-term effects
n chronic HF are unknown, cardiac arrhythmias and sud-
en death associated with the use of theophylline have been
eported previously.
Acetazolamide is a diuretic and respiratory stimulant
sed to treat idiopathic and high-altitude CSA. While
ther diuretics usually cause metabolic alkalosis, aceta-
olamide causes metabolic acidosis. The decrease in
H and [HCO3−] stimulates the chemoreceptors, eliciting
espiratory compensation and hypocapnoea due to hyper-
entilation. The short-term effects of acetazolamide were
ested for the treatment of CSA/CSR in 12 patients with
hronic HF [52]. The drug was administered in a dose
f 3.5 to 4.0mg/kg, 1 hour before bedtime for 6 nights,
ith a goal of decreasing total venous CO2 by approxi-
ately 5mmol/L, as evidence of its effect. This regimen
as associated with a mean AHI of 34± 20 versus 57± 28
uring the administration of placebo (p = 0.002). Acetazo-
amide lowered the number of central apnoeas despite the
ersistence of hypocapnoea. Its administration was asso-
iated with a decrease in venous and arterial CO2 and an
ncrease in arterial (H+), along with a decrease in pH and a
ecrease in arterial (HCO3−). It was hypothesised that the
ecrease in PCO2-driven apnoeic threshold was proportion-
lly greater than the decrease in blood PCO2. In that study,
ther effects of acetazolamide, including diuresis and allevi-
tion of pulmonary congestion, were minimal. As is the case
ith nearly all diuretics, acetazolamide increases the uri-
ary excretion of potassium, and may cause life-threatening
ypokalaemia, particularly in patients with chronic HF. The
dministration of acetazolamide raises other issues, such as
he stimulation of the respiratory muscles and hyperventi-
ation, which might accentuate the hypocapnoea observed
n patients with chronic HF, who may already be hyper-
entilating. Furthermore, by inducing metabolic acidosis,
cetazolamide may activate the sympathetic nervous sys-
em. Finally, because its long-term effects are unknown,
cetazolamide cannot be recommended as a routine treat-
ent.
The supplementation of inhaled air by CO2 during
leep-alleviated CSA/CSR in patients with chronic HF, an
bservation related to the key role played by hypocapnoea
n CSA/CSR [53]. In that study, the effects of inhal-
ng room air, CO2 or O2 mixtures were studied in ten
atients during stage 2 of a single overnight sleep study.
nce the patient was asleep, air was delivered through
facial mask coupled with a three-bag system allow-
ng the selection of one of the three gas mixtures. In a
rst trial, 10minutes after the onset of central apnoea,
C
NP. Bordier
mixture of 4% CO2, 21% O2 and 76% N2 was delivered.
he fraction of inspired CO2 was increased slowly until cen-
ral apnoeas and hypopnoeas were suppressed. The CO2
nhalation was continued for at least 10minutes before
witching the circuit to room air for 10minutes. There-
fter, random trials of CO2- or O2-enriched gas mixtures
ere separated by 10minutes of room air inhalation. O2
as administered in a sufﬁciently high concentration to
ncrease blood O2 saturation to the level reached dur-
ng CO2 inhalation. When the patients were not in stage 2
leep, the system was switched to room air. Transcutaneous
CO2, closely correlated with PaCO2, was measured con-
inuously. In the baseline, awake state, arterial PaO2 was
9.8± 18.5mmHg and PaCO2 was 34.3± 5.1mmHg. AHI dur-
ng room air was 38.7± 17.0 versus 2.3± 2.9 during CO2
nhalation (p < 0.0001). Only six patients underwent both
O2 and O2 inhalation trials, in whom a signiﬁcant 38%
ecrease (9.4± 7.0) in the apnoea index occurred during O2
nhalation, compared with room air inhalation, which was
ess pronounced than the 100% decrease (24.9± 7.3) caused
y CO2 inhalation. Although the inhalation of O2 decreased
he apnoea index, it had no signiﬁcant effect on AHI, indi-
ating either an absence of effect on hypopnoeas, or the
rogression from apnoeas to hypopnoeas. The time occu-
ied by central respiratory events was 82.9± 10.1% during
nhalation of room air versus 6.1± 9.5% (p = 0.01) during
O2 inhalation and 84.5± 17.1% during O2 inhalation. The
ain value of these studies pertain to the physiopathology
f CSA/CSR in chronic HF and the role played by hypocap-
oea; the routine therapeutic use of supplemental CO2
s not currently recommended. CO2 supplementation may
timulate the sympathetic system prominently, which is
ndesirable in patients with chronic HF. While increasing
he fraction of inspired CO2 by increasing the space of the
ask-tube of ventilatory devices is a simple manoeuvre,
t is neither suggested nor currently available in clinical
ractice.
onclusions
he therapeutic options available for the alleviation of sleep
pnoea in patients presenting with chronic HF are sum-
arized in Fig. 2. Their ability to decrease AHI is either
npredictable or partial, and, except in the case of OSA,
vidence of their effect on morbidity and mortality in
his patient population is lacking. The modest improve-
ents in cardiac performance that might be observed
uring the treatment of sleep apnoea in patients with
hronic HF are unlikely to systematically prolong life. In
ddition, the tolerance of systems using a nasal or facial
ask remains a frequent complicating factor, justifying the
onsideration of all available options in each individual
atient.onﬂicts of interest
one.
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[Figure 2. Treatment algorithm for sleep apnoea (SA) in patien
central (CSA) or mixed according to the predominant type of apnoe
Cheyne-Stokes respiration; CPAP: continuous positive airway pressu
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